Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?

Fan, Zhongqi; Xiaodong, Sun; Chen, Yuguo; Lv, Guoyue

doi:10.2174/1871520618666181114112431

Cited by 5 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 46 Besides, combined therapy is known to minimize medicine dosage, reduce drug toxicity, and boost effectiveness. 53 Therefore, it is reasonable to combine ST with other treatment modalities.…”

Section: Combined Therapy Targeting Glucose Metabolismmentioning

confidence: 99%

Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Li¹,

Li²,

Ai³

et al. 2022

IJN

View full text Add to dashboard Cite

Ordinarily, cancer cells possess features of abnormally increased nutrient intake and metabolic pathways. The disorder of glucose metabolism is the most important among them. Therefore, starvation therapy targeting glucose metabolism specifically, which results in metabolic disorders, restricted synthesis, and inhibition of tumor growth, has been developed for cancer therapy. However, issues such as inadequate targeting effectiveness and drug tolerance impede their clinical transformation. In recent years, nanomaterial-assisted starvation treatment has made significant progress in addressing these challenges, whether as a monotherapy or in combination with other medications. Herein, representative researches on the construction of nanosystems conducting starvation therapy are introduced. Elaborate designs and interactions between different treatment mechanisms are meticulously mentioned. Not only are traditional treatments based on glucose oxidase involved, but also newly sprung small molecule agents targeting glucose metabolism. The obstacles and potential for advancing these anticancer therapies were also highlighted in this review.

show abstract

Section: Combined Therapy Targeting Glucose Metabolismmentioning

confidence: 99%

Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Li¹,

Li²,

Ai³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Therefore, novel targeted therapeutic approaches are required to help overcome these problems. From a molecular-level perspective, an important HCC development factor is the imbalance of major signaling pathways, including Ras, p53, PI3K/Akt, and Wnt/β-catenin ( Saha and Giri, 2019 ; Zhongqi et al, 2019 ). Ras—a small-molecule GTPase member—has important regulatory functions in cell signal transduction, cytoplasmic skeletal construction, and material transport ( Ostrem et al, 2013 ; Lim et al, 2014 ; Lito et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Design, Synthesis, and Biological Evaluation of Pyrano[2,3-c]-pyrazole–Based RalA Inhibitors Against Hepatocellular Carcinoma

Wang

et al. 2021

Front. Chem.

View full text Add to dashboard Cite

The activation of Ras small GTPases, including RalA and RalB, plays an important role in carcinogenesis, tumor progress, and metastasis. In the current study, we report the discovery of a series of 6-sulfonylamide-pyrano [2,3-c]-pyrazole derivatives as novel RalA inhibitors. ELISA-based biochemical assay results indicated that compounds 4k–4r suppressed RalA/B binding capacities to their substrates. Cellular proliferation assays indicated that these RalA inhibitors potently inhibited the proliferation of HCC cell lines, including HepG2, SMMC-7721, Hep3B, and Huh-7 cells. Among the evaluated compounds, 4p displayed good inhibitory capacities on RalA (IC50 = 0.22 μM) and HepG2 cells (IC50 = 2.28 μM). Overall, our results suggested that a novel small-molecule RalA inhibitor with a 6-sulfonylamide-pyrano [2, 3-c]-pyrazole scaffold suppressed autophagy and cell proliferation in hepatocellular carcinoma, and that it has potential for HCC-targeted therapy.

show abstract

Immune checkpoint inhibitors for hepatocellular carcinoma

Nakka

2022

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

View full text Add to dashboard Cite

Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?

Cited by 5 publications

References 84 publications

Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Design, Synthesis, and Biological Evaluation of Pyrano[2,3-c]-pyrazole–Based RalA Inhibitors Against Hepatocellular Carcinoma

Immune checkpoint inhibitors for hepatocellular carcinoma

Contact Info

Product

Resources

About